Vulvovaginal Candidiasis (VVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Vulvovaginal Candidiasis (VVC) occurs when Candida species superficially penetrate the mucosal lining of the vagina and cause an inflammatory response. The dominant inflammatory cells are typically polymorphonuclear cells and macrophages. Patients may present with discharge, which is usually thick and adherent, excoriations, external dysuria, vaginal itching, vaginal burning, dyspareunia, or swelling. Risk factors for acute candidal vulvovaginitis include estrogen use, elevated endogenous estrogens, diabetes mellitus, immunosuppression, and broad-spectrum antibiotic use. Although candidal vulvovaginitis is more common in sexually active women, there is no evidence that candidal infection is sexually transmitted. Patients with recurrent candidal vulvovaginitis have predisposing genetic factors that cause them to be susceptible to recurrent fungal infections. These factors may also predispose to hypersensitivity to Candida. The most common responsible pathogen is C. albicans (in about 90% of cases), with most of the remaining cases caused by Candida glabrata.

• According to a survey conducted in the United States, approximately 5.2% of women experience vulvovaginal candidiasis (VVC) each year, and among those with VVC, 4.7% experience recurrent VVC (RVVC).
• Based on the estimated population of women aged 18 and older in the United States, around 6.8 million women experience VVC, and 325,000 experience RVVC each year.

 

Thelansis’s “Vulvovaginal Candidiasis (VVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vulvovaginal Candidiasis (VVC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Vulvovaginal Candidiasis (VVC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Vulvovaginal Candidiasis (VVC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Vulvovaginal Candidiasis (VVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033